SMIM24: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: SMIM24

NCBI ID: G284422

SMIM24

SMIM24: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can lead to significant disability and decreased quality of life. As a result, there is a growing interest in identifying potential drug targets and biomarkers for pain relief. One of the promising candidates is small integral membrane protein 24 (SMIM24), which has been identified as a potential drug target and biomarker for chronic pain.

SMIM24: Structural and Functional Characterization

SMIM24 is a 24-kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is localized to the endoplasmic reticulum and plays a role in cell signaling, particularly in the regulation of pain perception and neuroinflammation.

SMIM24 is composed of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain contains a putative intracellular signaling loop that is involved in the regulation of pain perception and neuroinflammation. The C-terminal cytoplasmic domain contains a unique structural feature called a \"secreted portion\" that is involved in protein-protein interactions and may play a role in SMIM24's functions.

SMIM24 has been shown to have pain-modulating properties in various experimental models. For instance, SMIM24 has been shown to reduce pain-induced by glutamate, a known mediator of pain, in rat neural neurons. Additionally, SMIM24 has been shown to protect against glutamate-induced pain in rat spinal cord neurons.

SMIM24 may also be a potential biomarker for chronic pain. The protein can be expressed and purified from various tissues, including pain-affected muscles and spinal cord, and its levels can be easily measured using techniques such as Western blotting. This makes SMIM24 an attractive candidate for use as a biomarker for tracking the effectiveness of pain treatments.

SMIM24 as a Drug Target

SMIM24's potential as a drug target is based on its involvement in the regulation of pain perception and neuroinflammation. The N-terminal transmembrane domain of SMIM24 has been shown to play a role in the regulation of pain-induced signaling pathways, including the production of pro-inflammatory cytokines.

Additionally, SMIM24's C-terminal cytoplasmic domain has been shown to interact with various signaling molecules, including serotonin and optic neuron-derived neurotrophic factor (ONNTF). This suggests that SMIM24 may be involved in the regulation of pain perception and neuroinflammation by modulating the activity of these molecules.

SMIM24 may be a useful drug target for the treatment of chronic pain by targeting its involvement in pain perception and neuroinflammation. For instance, SMIM24 has been shown to reduce pain-induced by glutamate in rat neural neurons. Additionally, SMIM24 may be able to protect against glutamate-induced pain in rat spinal cord neurons, making it an attractive candidate for use in neuroinflammation treatments.

SMIM24 as a Biomarker

SMIM24 may also be a useful biomarker for tracking the effectiveness of pain treatments. The protein can be expressed and purified from various tissues, including pain-affected muscles and spinal cord, and its levels can be easily measured using techniques such as Western blotting.

This makes SMIM24 an attractive candidate for use as a biomarker for tracking the effectiveness of pain treatments. For instance, by measuring the levels of SMIM24 in pain-affected muscles or spinal cord before and after treatment, researchers can determine whether treatment is effective in reducing pain levels.

Conclusion

SMIM24 is a promising candidate as a drug target and biomarker for chronic pain. Its involvement in the regulation of pain perception and neuroinflammation makes it an attractive target for the development of new pain treatments. Additionally, SMIM24's ease of expression and purification from various tissues makes it an attractive candidate for use as a biomarker in tracking the effectiveness of pain treatments. Further research is needed to fully understand the potential of SMIM24 as a drug target and biomarker for chronic pain.

Protein Name: Small Integral Membrane Protein 24

The "SMIM24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets